Maria Moksnes Bjaanæs

  • Consultant MD. PhD

Molecular characterisation of lung adenocarcinomas. Microarray analyses on miRNA, mRNA, DNA and methylation. Difference between EGFR-mutated and EGFR wild type tumours.

 

Publications 2019

Shao B, Bjaanæs MM, Helland Å, Schütte C, Conrad T (2019)
EMT network-based feature selection improves prognosis prediction in lung adenocarcinoma
PLoS One, 14 (1), e0204186
DOI 10.1371/journal.pone.0204186, PubMed 30703089

Zhang R, Lai L, Dong X, He J, You D, Chen C, Lin L, Zhu Y, Huang H, Shen S, Wei L, Chen X, Guo Y, Liu L, Su L, Shafer A, Moran S, Fleischer T, Bjaanaes MM, Karlsson A, Planck M, Staaf J, Helland Å, Esteller M, Wei Y et al. (2019)
SIPA1L3 methylation modifies the benefit of smoking cessation on lung adenocarcinoma survival: an epigenomic-smoking interaction analysis
Mol Oncol, 13 (5), 1235-1248
DOI 10.1002/1878-0261.12482, PubMed 30924596

Zhang R, Lai L, He J, Chen C, You D, Duan W, Dong X, Zhu Y, Lin L, Shen S, Guo Y, Su L, Shafer A, Moran S, Fleischer T, Bjaanæs MM, Karlsson A, Planck M, Staaf J, Helland Å, Esteller M, Wei Y, Chen F, Christiani DC (2019)
EGLN2 DNA methylation and expression interact with HIF1A to affect survival of early-stage NSCLC
Epigenetics, 14 (2), 118-129
DOI 10.1080/15592294.2019.1573066, PubMed 30665327

Publications 2018

Guo Y, Zhang R, Shen S, Wei Y, Salama SM, Fleischer T, Bjaanæs MM, Karlsson A, Planck M, Su L, Zhu Z, Staaf J, Helland Å, Esteller M, Christiani DC (2018)
DNA Methylation of LRRC3B: A Biomarker for Survival of Early-Stage Non-Small Cell Lung Cancer Patients
Cancer Epidemiol Biomarkers Prev, 27 (12), 1527-1535
DOI 10.1158/1055-9965.EPI-18-0454, PubMed 30185536

Shen S, Zhang R, Guo Y, Loehrer E, Wei Y, Zhu Y, Yuan Q, Moran S, Fleischer T, Bjaanaes MM, Karlsson A, Planck M, Staaf J, Helland Å, Esteller M, Su L, Chen F, Christiani DC (2018)
A multi-omic study reveals BTG2 as a reliable prognostic marker for early-stage non-small cell lung cancer
Mol Oncol, 12 (6), 913-924
DOI 10.1002/1878-0261.12204, PubMed 29656435

Wei Y, Liang J, Zhang R, Guo Y, Shen S, Su L, Lin X, Moran S, Helland Å, Bjaanæs MM, Karlsson A, Planck M, Esteller M, Fleischer T, Staaf J, Zhao Y, Chen F, Christiani DC (2018)
Epigenetic modifications in KDM lysine demethylases associate with survival of early-stage NSCLC
Clin Epigenetics, 10, 41
DOI 10.1186/s13148-018-0474-3, PubMed 29619118

Publications 2016

Eide HA, Halvorsen AR, Bjaanæs MM, Piri H, Holm R, Solberg S, Jørgensen L, Brustugun OT, Kiserud CE, Helland Å (2016)
The MYCN-HMGA2-CDKN2A pathway in non-small cell lung carcinoma--differences in histological subtypes
BMC Cancer, 16, 71
DOI 10.1186/s12885-016-2104-9, PubMed 26858029

Halvorsen AR, Bjaanæs M, LeBlanc M, Holm AM, Bolstad N, Rubio L, Peñalver JC, Cervera J, Mojarrieta JC, López-Guerrero JA, Brustugun OT, Helland Å (2016)
A unique set of 6 circulating microRNAs for early detection of non-small cell lung cancer
Oncotarget, 7 (24), 37250-37259
DOI 10.18632/oncotarget.9363, PubMed 27191990

Publications 2015

Bjaanæs MM, Fleischer T, Halvorsen AR, Daunay A, Busato F, Solberg S, Jørgensen L, Kure E, Edvardsen H, Børresen-Dale AL, Brustugun OT, Tost J, Kristensen V, Helland Å (2015)
Genome-wide DNA methylation analyses in lung adenocarcinomas: Association with EGFR, KRAS and TP53 mutation status, gene expression and prognosis
Mol Oncol, 10 (2), 330-43
DOI 10.1016/j.molonc.2015.10.021, PubMed 26601720

Publications 2014

Bjaanaes MM, Halvorsen AR, Solberg S, Jørgensen L, Dragani TA, Galvan A, Colombo F, Anderlini M, Pastorino U, Kure E, Børresen-Dale AL, Brustugun OT, Helland A (2014)
Unique microRNA-profiles in EGFR-mutated lung adenocarcinomas
Int J Cancer, 135 (8), 1812-21
DOI 10.1002/ijc.28828, PubMed 24599520

Page visits: 2944